Plus Therapeutics Secures 45.4 Million Coverage, Raising CNSide Assay Coverage to 126 Million
PSTV•Plus Therapeutics subsidiary CNSide Diagnostics secured national Elevance Health coverage effective May 1, adding 45.4 million lives and raising CNSide CSF assay coverage to 126 million. Over 11,000 tests at 120+ institutions have demonstrated 92% sensitivity, 95% specificity and influenced treatment decisions in 90% of cases.
1. National Coverage Agreement
On May 1, Plus Therapeutics’ subsidiary CNSide Diagnostics signed a national coverage agreement with Elevance Health covering approximately 45.4 million additional people. This agreement brings the total contracted coverage for the CNSide CSF Tumor Cell Enumeration assay to 126 million lives in the United States.
2. Assay Performance and Adoption
Since 2020, the CNSide CSF assay has been performed more than 11,000 times at over 120 U.S. cancer institutions. The test delivers high sensitivity (92%) and specificity (95%) and has influenced treatment decisions in 90% of cases, demonstrating strong clinical utility.
3. Market Impact and Expansion Prospects
The expanded coverage positions CNSide Diagnostics for broader adoption among healthcare providers and potential revenue growth. Exclusive availability through CNSide Diagnostics supports the assay’s market penetration and underpins future commercialization efforts by Plus Therapeutics.
